Improved survival using specialized multidisciplinary board in sarcoma patients

Area of Science:

• Oncology
• Clinical Management
• Public Health

Background:

• Sarcomas are rare, aggressive cancers requiring specialized care.
• Multidisciplinary tumor board (MDTB) management is not universally implemented.
• This study evaluates the impact of pre-treatment MDTB presentation on sarcoma patient outcomes.

Purpose of the Study:

• To investigate the effect of multidisciplinary tumor board (MDTB) presentation before treatment on sarcoma patient management and survival.
• To assess compliance with clinical practice guidelines in sarcoma care.
• To analyze the nationwide impact of a specialized sarcoma network.

Main Methods:

• A nationwide study in France involving 12,528 sarcoma patients (≥15 years) from 2010-2014.
• Patients were analyzed based on whether they were presented to a multidisciplinary tumor board (MDTB) before or after initial treatment.
• Data collected through the NETSARC network, including patient characteristics, management, and follow-up.

Main Results:

• 42.2% of patients were presented to an MDTB before treatment; these patients often had worse prognostic factors.
• Pre-treatment MDTB presentation correlated with better adherence to guidelines (biopsy, imaging, surgery quality) and fewer reoperations (P < 0.001).
• Significantly improved local relapse-free survival and relapse-free survival were observed in patients treated after pre-treatment MDTB consultation (univariate and multivariate analysis).

Conclusions:

• Pre-therapeutic multidisciplinary tumor board (MDTB) guidance significantly enhances sarcoma patient compliance with clinical practice guidelines.
• Early MDTB involvement leads to improved relapse-free survival for sarcoma patients.
• Specialized, multidisciplinary management prior to treatment is critical for optimizing sarcoma outcomes.